C. Page (London, United Kingdom), M. Contoli (Ferrara , Italy)
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
S. D. Lee, C. M. Xie, F. Yunus, Y. Itoh, R. Su (Seoul, Republic Of Korea; Guangzhou, Shanghai, China; Jakarta, Indonesia; Osaka, Japan)
|  |
Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD
F. Maltais, J. B. Gáldiz Iturri, A. Kirsten, D. Singh, A. Hamilton, K. Tetzlaff, Y. Zhao, R. Casaburi (Québec, Burlington, Canada; Barakaldo, Spain; Grosshansdorf, Ingelheim, Germany; Manchester, United Kingdom; Ridgefield, Los Angeles, United States Of America)
|  |
Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials
J. M. Hohlfeld, A. Furtwaengler, M. Könen-Bergmann, G. Wallenstein, B. Walter, E. D. Bateman (Hannover, Ingelheim, Limburgerhof, Germany; Cape Town, South Africa)
| |
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
E. Bateman, S. Rennard, P. Jones, E. Molins, M. Jin, A. Leselbaum (Cape Town, South Africa; Omaha, Jersey City, United States Of America; London, United Kingdom; Barcelona, Spain)
| |
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
A. D'Urzo, S. Rennard, E. Kerwin, V. Mergel, T. He, A. Leselbaum, C. Caracta (Toronto, Canada; Omaha, Medford, Jersey City, United States Of America; Barcelona, Spain)
| |
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
J. F. Donohue, E. D. Bateman, A. D'Urzo, P. Shrestha, A. Leselbaum, A. Lei (Chapel Hill, United States Of America; Cape Town, South Africa; Toronto, Canada; Barcelona, Spain)
| |
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
A. D'Urzo, D. A. Mahler, P. Olsson, H. Chen, R. Fogel, D. Banerji (Toronto, Canada; Dartmouth, East Hanover, United States Of America; Basel, Switzerland)
| |
Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
R. Dahl, R. Buhl, K. Mezzi, A. Schubert-Tennigkeit, H. Chen, D. Banerji, R. Fogel (Odense, Denmark; Mainz, Germany; Basel, Switzerland; East Hanover, United States Of America)
| |
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
D. Singh, S. Worsley, C. Q. Zhu, L. Hardaker, A. Church (Manchester, London, United Kingdom; Research Triangle Park, United States Of America)
| |
Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5mcg and VI 25mcg in COPD patients
J. F. Donohue, D. Singh, C. Munzu, S. Kilbride, A. Church (Chapel Hill, Research Triangle Park, United States Of America; Manchester, London, United Kingdom)
| |
Effect of cold stimulation over face on 6 minute walk distance (6MWD), oxygen saturation and dyspnea scores in patients with COPD
S. Rasam, D. Salvi, Y. Thorat, S. Salvi, R. Kodgule (Pune, India)
| |
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
M. Moretti (Carrara, Italy)
| |
Long-term efficacy of A1-PI therapy in RAPID and its extension study
N. G. McElvaney, K. R. Chapman, J. Burdon, E. Piitulainen, N. Seersholm, J. Stocks, R. Sandhaus, J. Edelman, M. Bexon, L. Huang (Dublin, Ireland; Toronto, Canada; Melbourne, Australia; Malmo, Sweden; Hellerup, Denmark; Tyler, Denver, King of Prussia, United States Of America; Bern, Switzerland)
| |
Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma
J. Beier, D. Singh, R. Fuhr, S. Ruiz, B. Seoane, E. Massana, E. Jimenez, H. Pujol, C. Astbury, G. De Miquel (Wiesbaden, Berlin, Germany; Manchester, United Kingdom; Barcelona, Spain)
| |
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma
W. Anderson, P. Short, P. Williamson, A. Manoharan, B. Lipworth (Dundee, United Kingdom)
| |
Benralizumab effect on blood basophil counts in adults with uncontrolled asthma
S. Eck, M. Castro, D. Sinibaldi, W. White, K. Folliot, D. Gossage, Y. Wu, D. Raible, L. Roskos, R. Kolbeck, C. Ward (Gaithersburg, St. Louis, Seattle, United States Of America)
| |
HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma
V. Backer, J. C. Virchow, H. H. Villesen, P. A. Fejerskov, B. Riis, F. De Blay (Copenhagen, Hørsholm, Denmark; Rostock, Germany; Strasbourg, France)
| |
A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
L. Bjermer, C. Lemiere, J. Maspero, M. Ciesielska, C. O'Brien, J. Zangrilli (Lund, Sweden; Montreal, Canada; Buenos Aires, Argentina; Frazer, United States Of America)
| |